Please login to the form below
Vaxigrip
This page shows the latest Vaxigrip news and features for those working in and with pharma, biotech and healthcare.
AZ wins EU approval for four-strain flu vaccine
Sanofi is still to have its four-strain vaccine recommended in the EU, however, although it was accepted for review by the EMA under the brand name Vaxigrip in April. ... The vaccine is also approved for the youngest patient population in Europe, as
Latest news
-
Sanofi’s four-strain flu vaccine Vaxigrip under review in EU
Pharma company also launches production of ingredient for malaria drug. Sanofi's four-strain (quadrivalent) influenza vaccine Vaxigrip has been accepted by the European Medicines Agency (EMA) for review for approval ... If approved, Vaxigrip will be
-
Sanofi has 65 new compounds in development, says R&D chief
hexavalent vaccine (DTP-Hep B-Polio-Hib), as well as a filing in the EU for Sanofi's quadrivalent flu vaccine Vaxigrip QIV.
Sanofi’s four-strain flu vaccine Vaxigrip under review in EU
Sanofi has 65 new compounds in development, says R&D chief
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Assessing the value of interim analyses in clinical trials
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- AZ’s Imfinzi combination shows promise in liver cancer
- Gilead’s Trodelvy set for EU approval in breast cancer
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Novo Nordisk settles US insulin pricing dispute for $100m
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- bluebird bio provides update on 2seventy bio spin-off
- Award-winning health agency 90TEN launches in the US
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
